Alice Chen is the Principal at Accelerator Corporation, a venture-backed investment vehicle based in Seattle, Washington for identifying, evaluating, financing, and managing innovative life science opportunities from a broad range of proprietary sources. As the Principal, Alice focuses on portfolio company operations as well as sourcing and scientifically evaluating emerging biotechnologies for Accelerator.
Alice is particularly interested in early-stage life science technologies that have the potential to address critical problems and underserved medical needs. To manage the intrinsic risks associated with early-stage developments, Alice aims to establish a rigorous and streamlined diligence process and construct a well-defined development path for each Accelerator portfolio company.
Before joining Accelerator in 2013, Alice served as a scientific and project management consultant for several biotechnology companies. Prior to her consulting role, she was the Director of Technologies at Qwell Pharmaceuticals, a venture-backed biotechnology company developing novel, small-molecule drugs focused on cancer and inflammation.
Education, Personal, and Fellowship
Alice received her PhD in chemical engineering from Stanford University as the Stanford Gerald Lieberman Fellow. Her doctoral work focused on protein engineering and protein characterization. She received her BS in chemical engineering from UC Berkeley as a Regents Scholar, and was an Engineering Fellow at Merck & Co.
As a member of Class 19, Alice served her fellowship at Accelerator Corporation under the mentorship of CEO Thong Le and CSO Dr. David McElligott.